The use of the drug Refnot® (α-tumor necrosis factor-thymosin-α1) in patients with disseminated skin melanoma
Reshetov I.V., Reshetnikov A.V., Abramov A.A., Kirpa-Ivanova E.A., Pimanchev P.V.
(I.M. Sechenov First Moscow State Medical University)
Presentation of the report at the XXIII Congress of the European Association for cranio-maxillo-facial surgery (13.09-16.09.2016, London, United Kingdom).
Interferon Gamma, Tumor Necrosis Factor – Thymosin Alpha-1 – Anti-Infective and Anti-Tumor Cytokines and Drugs
REFNOT. Recombinant Tumor Necrosis Factor – Thymosin-α1, the Drug with Low Systemic Toxicity for the Treatment of Oncology Diseases
Refnot® — New Immunomodulator for the Treatment of Oncology Patients
Refnot – New National Immunomodulator for the Treatment of Melanoma
Refnot® – New Immunomodulator of Antineoplastic Action
Refnot® — New Highly Efficient Immunomodulator for the Treatment of Oncology Patients
REFNOT. Recombinant Tumor Necrosis Factor – Thymosin-α1, Highly Efficient Drug with Low Systemic Toxicity for the Treatment of Oncology Diseases
The Impact of Refnot Drug on Oncology Patients’ Immunity
The Impact of Refnoton Oncology Patients’ Immunity
Новости 1 - 10 of 15
First | Prev. | 1 2 | Next | Last